Relevance of Metabolic Activation Pathways: The Example of Clopidogrel and Prasugrel

Abstract

Poor or lacking responses to the antiplatelet effect of clopidogrel (CAS 113665-84-2) and the attendant clinical consequences have been a growing concern for several years. This debate has been invigorated by reports suggesting the ability of inhibitors of the cytochrome P450 isoenzyme, CYP 2C19, to interfere with clopidogrel efficacy. In the present review, the mechanisms underlying clopidogrel failure are analyzed, based on an overview of the current perceptions of drug metabolismby the CYP superfamily of enzymes, and paying particular attention to the relevant properties of the newly introduced thienopyridine, prasugrel (CAS 150322-43-3). Convincing evidence indicates that the vulnerability of clopidogrel lies in its mode of activation. In a two-step sequence, both crucially dependent on the function of CYP 2C19, about 15% of a given dose of clopidogrel are converted into an active metabolite. Thus, activation is at risk or impossible in patients with the phenotype of an intermediate or poor metabolizer or, for similar reasons, in patients co-administered with a CYP 2C19 inhibitor such as the proton pump inhibitor (PPI), omeprazole. Theoretical and experimental data suggest that other PPIs such as rabeprazole do not share this ability. As opposed to clopidogrel, administered prasugrel is practically completely activated. At first sight a similar two-step process, this activation shows distinct differences: The first metabolic step is mediated by carboxylesterases and the second reaction is catalyzed by five different CYP isoenzymes, with no pivotal role for CYP 2C19 or any other CYP isoform. This setting allows the prediction that neither specific genetic traits nor pharmacokinetic drug interactions will interfere with prasugrel antiplatelet activity. Unfolding evidence, including a lack of interference by genotype and CYP 2C19 or CYP 3A4 inhibitors, has confirmed this expectation. The robust efficacy of prasugrel allows the prediction that this new thienopyridine will provide an unproblematic treatment modality, with no need for pheno- or genotyping and no special regards for co-administered drugs.

Key words

CAS 113665-84-2 - CAS 150322-43-3 - Clopidogrel - Cytochrome P450 - Drug interactions - Omeprazole - Polymorphism - Prasugrel - Proton pump inhibitors

• References

• 1 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E et al. Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler Thromb Vasc Biol. 2006; 26: 1895-1900
• 2 Angiolillo DJ, Alfonso F. Clopidogrel-statin interaction: myth or reality?. J AmColl Cardiol. 2007; 50: 296-298
• 3 Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Alfonso F, Macaya C, Bass TA et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol. 2007; 49: 1505-1516
• 4 Aubert RE, Epstein RS, Teagarden JR, Xia F, Yao J, Desta Z et al. Proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel Medco outcomes study (abstract). Circulation. 2008; 118: S815
• 5 Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007; 28: 1598-1660
• 6 Becker ML, Visser LE, Trienekens PH, Hofman A, van Schaik RH, Stricker BH. Cytochrome P450 2C9 *2 and *3 polymorphisms and the dose and effect of sulfonylurea in type II diabetes mellitus. Clin Pharmacol Ther. 2008; 83: 288-292
• 7 Beitelshees AL, McLeod HL. Clopidogrel pharmacogenetics: promising steps towards patient care?. Arterioscler Thromb Vasc Biol. 2006; 26: 1681-1683
• 8 Brandolese R, Scordo MG, Spina E, Gusella M, Padrini R. Severe phenytoin intoxication in a subject homozygous for CYP2C9*3. Clin Pharmacol Ther. 2001; 70: 391-394
• 9 Brandt JT, Payne CD, Wiviott SD, Weerakkody G, Farid NA, Small DS et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J. 2007; a 153 (66) e9-16
• 10 Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd et al. Common polymorphisms of CYP 2C19 and CYP 2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007; b 5: 2429-2436
• 11 Calatzis A. Another view on prasugrel. Thromb Haemost. 2009; 101: 12-13
• 12 Cashman JR, Perotti BY, Berkman CE, Lin J. Pharmacokinetics and molecular detoxication. Environ Health Perspect. 1996; 104 (Suppl 1) 23-40
• 13 Cattaneo M. ADP receptors: inhibitory strategies for antiplatelet therapy. Drug News Perspect. 2006; 19: 253-259
• 14 Chen BL, Zhang W, Li Q, Li YL, He YJ, Fan L et al. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP 2C19 genetic polymorphisms. Clin Exp Pharmacol Physiol. 2008; 35: 904-908
• 15 Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 2003; 31: 53-59
• 16 Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373: 309-317
• 17 Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998; 57: 107-116
• 18 Cytochrome P450 (CYP) Allele Nomenclature Committee. Allele nomenclature for Cytochrome P450 enzymes at http://www.cypalleles.ki.se (accessed on March 22, 2009)
• 19 Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006; 45: 13-31
• 20 DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA. Functional characterization of novel allelic variants of CYP 2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005; 315: 1085-1090
• 21 Ding Z, Kim S, Dorsam RT, Jin J, Kunapuli SP. Inactivation of the human P2Y₁₂ receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood. 2003; 101: 3908-3914
• 22 Dunn SP, Macaulay TE, Brennan DM, Campbell CL, Charnigo RJ, Smyth SS et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation. 2008; 118: S 815
• 23 Eap CB, Bender S, Jaquenoud Sirot E, Cucchia G, Jonzier-Perey M et al. Nonresponse to clozapine and ultrarapid CYP 1A2 activity: clinical data and analysis of CYP 1A2 gene. J Clin Psychopharmacol. 2004; 24: 214-219
• 24 Emilien G, Ponchon M, Caldas C, Isacson O, Maloteaux JM. Impact of genomics on drug discovery and clinical medicine. Q J Med. 2000; 93: 391-423
• 25 Evans WE, McLeod HL. Pharmacogenomics — disposition, drug targets, and side effects. N Engl J Med. 2003; 348: 538-549
• 26 Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos. 2007; a 35: 1096-1104
• 27 Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS, 2nd Brandt JT. et al. Cytochrome P450 3A inhibition by ketoco-nazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 2007; b 81: 735-741
• 28 Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG et al. Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy. 2008; 28: 1483-1494
• 29 FDA. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix), 2009 available at http://www.fda.gov/cder/drug/early_comm/clopidogrel_bisulfate.htm (accessed on March 22, 2009)
• 30 Flockhart DA. Drug Interactions: Cytochrome P450 Drug Interaction Table. Indiana University School of Medicine; available at http://medicine.iupui.edu/flockhart/table.htm (accessed on February 19, 2009
• 31 Fontana P, Hulot JS, Moerloose P, Gaussem P. Influence of CYP 2C19 and CYP 3A4 gene polymorphism on clopidogrel responsiveness in healthy subjects. J Thromb Haemost. 2007; 5: 2153-2155
• 32 Fontana P, Senouf D, Mach F. Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness. Thromb Res. 2008; 121: 463-468
• 33 Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol. 2008; 101: 1088-1093
• 34 Friesen MH. Issues that limit study conclusions. CMAJ available at http://www.cmaj.ca/cgi/eletters/cmaj.082001v1#53931 (accessed on March 22, 2009)
• 35 Gatanaga H, Hayashida T, Tsuchiya K, Yoshino M, Kuwahara T, Tsukada H et al. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis. 2007; 45: 1230-1237
• 36 Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C et al. CYP 2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics. 2008; 9: 1251-1259
• 37 Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4: 2508-2509
• 38 Gilard M, Arnaud B, Cornily JC, Le Gal G, Lacut K, Le Calvez G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole Clopidogrel Aspirin) study. J AmColl Cardiol. 2008; 51: 256-260
• 39 Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP 3A4 IVS10 + 12G/A and P2Y₁₂ T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics. 2007; 17: 1057-1064
• 40 Guengerich FP. Characterization of human cytochrome P450 enzymes. FASEB J. 1992; 6: 745-748
• 41 Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J. 8 2006; E101-E111
• 42 Hagihara K, Nishiya Y, Kurihara A, Kazui M, Farid NA, Ikeda T. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine. Drug Metab Pharmacokinet. 2008; 23: 412-420
• 43 Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301: 937-944
• 44 Huang CW, Lai ML, Lin MS, Lee HL, Huang JD. Dose-response relationships of propranolol in Chinese subjects with different CYP 2D6 genotypes. J Chin Med Assoc. 2003; 66: 57-62
• 45 Ieiri I, Kimura M, Irie S, Urae A, Otsubo K, Ishizaki T. Interaction magnitude, pharmacokinetics and pharmacodynamics of ticlopidine in relation to CYP 2C19 genotypic status. Pharmacogenet Genomics. 2005; 15: 851-859
• 46 Imai T. Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet. 2006; 21: 173-185
• 47 Ingelman-Sundberg M, Rodriguez-Antona C. Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Phil Trans R Soc B. 2005; 360: 1563-1570
• 48 Inomata S, Nagashima A, Itagaki F, Homma M, Nishimura M, Osaka Y et al. CYP 2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin Pharmacol Ther. 2005; 78: 647-655
• 49 Ismail R, Teh LK. The relevance of CYP 2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients. J Clin Pharm Ther. 2006; 31: 99-109
• 50 Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006; 27: 1166-1173
• 51 Juurlink DN, Gomes T, Ko DT, Szmitko PE, Austin PC, Tu JV, et al. (version subject to revision). A populationbased study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; Epub ahead of print, available at http://www.cmaj.ca/cgi/rapidpdf/cmaj 082001v1 (accessed on March 22, 2009)
• 52 Kim KA, Park PW, Park JY. Effect of CYP3A5*3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 2008; a 64: 589-597
• 53 Kim KA, Park PW, Hong SJ, Park JY. The effect of CYP 2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 2008; b 84: 236-242
• 54 Krämer SD, Testa B. The biochemistry of drug metabolism – An introduction. Part 6. Inter-individual factors affecting drug metabolism. Chem Biodivers. 2008; 5: 2465-2578
• 55 Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M et al. multiple novel nonsynonymous CYP 2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles. J Pharmacol Exp Ther. 2004; 311: 34-41
• 56 Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation. 2003; 107: 32-37
• 57 Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004; 109: 166-171
• 58 Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Curr Clin Pharmacol. 2006; 1: 5-20
• 59 Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004; 32: 821-827
• 60 Ma MK, Woo MH, Mcleod HL. Genetic basis of drug metabolism. AmJ Health Syst Pharm. 2002; 59: 2061-2069
• 61 Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G et al. Coexisting polymorphisms of P2Y₁₂ and CYP 2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J. 2008; 72: 1165-1169
• 62 Medsafe. Data Sheet Clopidogrel hydrogen sulfate. available at http://www.medsafe.govt.nz/Profs/Datasheet/p/Plavixtab.htm (accessed on March 14, 2009)
• 63 Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360: 354-362 (see also supplementary material)
• 64 Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373: 723-731
• 65 Mosca L, Arnett DK, Dracup K, Hansen BC, Labarthe DR, Marks JS et al. American Heart Association. Task Force on Strategic Research Direction. Population/Outcomes/Epidemiology/Social Science Subgroup. Circulation. 2002; 106: e167-172
• 66 Mullangi R, Srinivas NR. Clopidogrel: review of bioanalytical methods, pharmacokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies. Biomed Chromatogr. 2009; 23: 26-41
• 67 Nakajima M, Yokoi T, Mizutani M, Shin S, Kadlubar FF, Kamataki T. Phenotyping of CYP 1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP 1A2 gene. Cancer Epidemiol Biomarkers Prev. 1994; 3: 413-421
• 68 Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics. 1996; 6: 1-42
• 69 Petersen KU. From toxic precursors to safe drugs. Mechanisms and relevance of idiosyncratic drug reactions. Arzneimittelforschung. 2002; 52: 423-429
• 70 Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001; 286: 2270-2279
• 71 Rehmel JLF, Eckstein JA, Farid NA, Heim JB, Kasper S, Kurihara A et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metabol Dispos. 2006; 34: 600-607
• 72 Rodrigues AD, Rushmore TH. Cytochrome P450 pharmacogenetics in drug development: in vitro studies and clinical consequences. Curr Drug Metab. 2002; 3: 289-309
• 73 Rosemary J, Adithan C. The pharmacogenetics of CYP 2C9 and CYP2C19: Ethnic variation and clinical significance. Curr Clin Pharmacol. 2007; 2: 93-109
• 74 Savi no-ginvennames, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000; 84: 891-896
• 75 Savi P, Combalbert J, Gaich C, Rouchon MC, Maffrand JP, Berger Y et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450-1A. Thromb Haemost. 1994; 72: 313-317
• 76 Siller-Matula JM, Spiel AO, Lang IM, Kreiner G, Christ G, Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157: 148.e1-5
• 77 Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009; 360: 363-375
• 78 Sindrup SH, Brøsen K. The pharmacogenetics of codeine hypoalgesia. Pharmacogenetics. 1995; 5: 335-346
• 79 Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 2008; 48: 475-484
• 80 Steward DJ, Haining RL, Henne KR, Davis G, Rushmore TH, Trager WF et al. Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics. 1997; 7: 361-367
• 81 Sugidachi A, Ogawa T, Kurihara A, Hagihara K, Jakubowski JA, Hashimoto M et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007; 5: 1545-1551
• 82 Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ et al. Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ. 2006; 74: 1715-1722
• 83 Terpening C. An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. J Am Board Fam Med. 2009; 22: 51-56
• 84 Testa B, Krämer SD. The biochemistry of drug metabolism – An introduction. Part 1. Principles and overview. Chem Biodivers. 2006; 3: 1053-1101
• 85 Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective PCI with drug-eluting or bare-metal stents. J Am Coll Cardiol. 2008; 51: 1925-1934
• 86 Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA et al. Prasugrel achieves greater and faster P2Y₁₂ receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008; 29: 21-30
• 87 Wang H, Tompkins LM. CYP 2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab. 2008; 9: 598-610
• 88 Wehling M. Translational Medicine: What is it and what could it be?. Arzneimittelforschung. 2009; 59: 3-7
• 89 Williams ET, Jones KO, Ponsler GD, Lowery SM, Perkins EJ, Wrighton SA et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos. 2008; 36: 1227-1232
• 90 Wiviott SD, Antman EM. Clopidogrel resistance: a new chapter in a fast-moving story. Circulation. 2004; 109: 3064-3067
• 91 Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M et al. Role of polymorphic human CYP 2B6 in cyclophosphamide bioactivation. Pharmacogenomics J. 2003; 3: 53-61
• 92 Yoneda K, Iwamura R, Kishi H, Mizukami Y, Mogami K, Kobayashi S. Identification of the active metabolite of ticlo-pidine from rat in vitro metabolites. Br J Pharmacol. 2004; 142: 551-557
• 93 Zheng H, Webber S, Zeevi A, Schuetz E, Zhang J, Bowman P et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP 3A5 and MDR1 gene polymorphisms. Am J Transplant. 2003; 3: 477-483